文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

严重肺炎中糖皮质激素的真实世界使用:一项倾向评分匹配研究

Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study.
PubMed 文献 · Crit Care · 2021-12-16
一句话结论在伴脓毒性休克和/或需有创机械通气、炎症反应高的严重社区获得性肺炎患者中,糖皮质激素可能降低28天死亡率(HR 0.53),无上述特征者未见获益。

该研究分析巴塞罗那和罗马两个前瞻性观察队列中因严重社区获得性肺炎(CAP)入住ICU且炎症反应高的患者,用倾向评分匹配平衡基线变量,并排除病毒性肺炎或接受氢化可的松者。610例严重CAP中198例(32%)接受糖皮质激素,387例符合严重CAP主要标准;所有患者基线C反应蛋白均高于15 mg/dL。匹配后,符合主要严重标准(有创机械通气 and/or 脓毒性休克)的89例患者中,接受糖皮质激素者28天死亡率18%(16例)低于未接受者31%(28例),p=0.037;匹配后HR 0.53(95%CI 0.29-0.98),p=0.043。不符合主要严重标准者未见获益(HR 0.88,95%CI 0.32-2.36)。作者认为糖皮质激素可能对伴脓毒性休克和/或高炎症反应且需要有创机械通气的CAP患者有益,无这些特征时对死亡率似乎无影响。

要点

  • 严重CAP伴脓毒性休克和/或需有创机械通气且炎症反应高者,糖皮质激素可能降低28天死亡率:匹配后HR 0.53(95%CI 0.29-0.98),p=0.043。
  • 不符合同样主要严重标准者未见获益:HR 0.88(95%CI 0.32-2.36)。
  • 匹配前,接受糖皮质激素者28天死亡率18%(16例)低于未接受者31%(28例),p=0.037。
  • 所有纳入患者基线C反应蛋白均高于15 mg/dL;研究排除病毒性肺炎或接受氢化可的松者。
  • 610例严重CAP中198例(32%)接受糖皮质激素,387例符合严重CAP主要标准。

适用人群与场景

  • 巴塞罗那和罗马两个前瞻性观察队列中因社区获得性肺炎(CAP)入住ICU且炎症反应高的患者。
  • 排除病毒性肺炎或接受氢化可的松的患者。
  • 全部患者基线血清C反应蛋白高于15 mg/dL。

诊断标准与关键阈值

  • 严重CAP主要标准:需要有创机械通气和/或脓毒性休克。

研究设计与关键结果

  • 研究类型:两个前瞻性观察队列的倾向评分匹配分析;610例严重CAP中198例(32%)接受糖皮质激素,387例符合严重CAP主要标准。
  • 接受糖皮质激素者更多为男性、合并症更多(如癌症或慢性阻塞性肺疾病),序贯器官衰竭评估评分显著更高。
  • 89例符合主要严重标准(有创机械通气和/或脓毒性休克)者按组匹配;28天死亡率接受糖皮质激素者18%(16例)低于未接受者31%(28例),p=0.037。
  • 倾向评分匹配后,符合主要严重标准者接受糖皮质激素的28天死亡风险降低:HR 0.53(95%CI 0.29-0.98),p=0.043。
  • 不符合主要严重标准者未见获益:HR 0.88(95%CI 0.32-2.36)。

证据类型、等级与局限

  • 证据类型:两个前瞻性观察队列的倾向评分匹配研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,糖皮质激素治疗可能对伴脓毒性休克和/或高炎症反应且需要有创机械通气的CAP患者有益。
  • 作者认为,不具备这些特征时糖皮质激素对死亡率似乎无影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality worldwide despite correct antibiotic use. Corticosteroids have long been evaluated as a treatment option, but heterogeneous effects on survival have precluded their widespread implementation. We aimed to evaluate whether corticosteroids might improve clinical outcomes in patients with severe CAP and high inflammatory responses.

STUDY DESIGN AND METHODS: We analyzed two prospective observational cohorts of patients with CAP in Barcelona and Rome who were admitted to intensive care with a high inflammatory response. Propensity score (PS) matching was used to obtain balance among the baseline variables in both groups, and we excluded patients with viral pneumonia or who received hydrocortisone.

RESULTS: Of the 610 patients admitted with severe CAP, 198 (32%) received corticosteroids and 387 had major criteria for severe CAP. All patients had a baseline serum C-reactive protein above 15 mg/dL. Patients who received corticosteroids were more commonly male, had more comorbidities (e.g., cancer or chronic obstructive pulmonary disease), and presented with significantly higher sequential organ failure assessment scores. Eighty-nine patients met major severity criteria (invasive mechanical ventilation and/or septic shock) and were matched per group. Twenty-eight-day mortality was lower among patients receiving corticosteroids (16 patients, 18%) than among those not receiving them (28 patients, 31%; p = 0.037). After PS matching, corticosteroid therapy reduced the 28-day mortality risk in patients who met major severity criteria (hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.29-0.98) (p = 0.043). In patients who did not meet major severity criteria, no benefits were observed with corticosteroid use (HR 0.88 (95%CI 0.32-2.36).

CONCLUSIONS: Corticosteroid treatment may be of benefit for patients with CAP who have septic shock and/or a high inflammatory response and requirement for invasive mechanical ventilation. Corticosteroids appear to have no impact on mortality when these features are not present.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ceccato A, Russo A, Barbeta E, et al. Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. Crit Care. 2021. PMID: 34915895. doi:10.1186/s13054-021-03840-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。